SciELO - Scientific Electronic Library Online

 
vol.19 issue3Micophenolate mofetil (MMF) in the idiopathic nephrotic syndrome (SNI) resistantance to different treatmentsDiagnostic approach to hip pain in children author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Iatreia

Print version ISSN 0121-0793

Abstract

CARMONA-FONSECA, Jaime. High efficacy of primary chemoprophylaxis with primaquine: metanalysis. Iatreia [online]. 2006, vol.19, n.3, pp.244-260. ISSN 0121-0793.

BACKGROUND : There are many reportss about primaquine as primary chemoprophylactic (1-CP) in humans, but we do not know of any metaanalysis about this subject. SPECIFIC QUESTIONS : Is primaquine effective to prevent malaria in humans? Does primaquine efficacy to prevent malaria depend on the place, the age of patients, or the Plasmodium species? METHODOLOGY : Procedures recommended for metanalysis were applied. RESULTS : Four laboratory experimental studies (LES) in humans and seven clinical controlled studies (CCS) were included. According to LES the adequate primaquine dose as 1-CP for adults is 30 mg/day from the day before exposition and during the time of exposition. According to CCS protection was 93% in people that received primaquine and 45% in those who did not receive it (p = 0.0000000). CONCLUSIONS : Primaquine is highly effective for 1- CP of malaria, its efficacy is similar against both P. falciparum and P. vivax, it protects adults as well as children and 1-CP with primaquine must be adopted as a valid alternative. Field studies are necessary in order to know the security and toxicity in children younger than eight years.

Keywords : FALCIPARUM; MALARIA; META-ANALYSIS; PALUDISM; PLASMODIUM; PRIMAQUINE; PRIMARY PROPHYLAXIS; VIVAX.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License